MK-2206 2HCl

製品コードS1078

MK-2206 2HCl化学構造

分子量(MW):480.39

MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。

サイズ 価格 在庫  
JPY 31677.36 あり
JPY 15838.68 あり
JPY 24477.96 あり
JPY 53275.56 あり
JPY 82073.16 あり

文献中の引用(180)

カスタマーフィードバック(19)

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

製品安全説明書

Akt阻害剤の選択性比較

生物活性

製品説明 MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。
特性 The first allosteric small molecule inhibitor of Akt to enter clinical development.
ターゲット
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外試験

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MlvLR5l1d3SxeHnjJGF{e2G7 MlfCN{DPxE1? MojqO|IhcA>? MnHtSG1UVw>? NXe3SY84UW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NHLOR2gzODV5MUC2PS=>
A431 M4XT[mtqdmG|ZTDBd5NigQ>? MkPSOUDPxE1? M2jid|UhcA>? NVnWcZJYTE2VTx?= MoD1V5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs MnTmNlA2PzFyNkm=
HepG2 M4DTU2N6fG:2b4jpZ{BCe3OjeR?= MoHKNVAh|ryP MnOxNlQhcA>? MVjEUXNQ NGLMeY1U\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> MkXNNlEzODV7MkW=
Sk-Hep1 NEC4fppEgXSxdH;4bYMhSXO|YYm= M3zXWVExKM7:TR?= NH3GXHIzPCCq MmrjSG1UVw>? MmDyV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni MlfsNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuN{DPxE1? M2PE[VUh\A>? MnS1SG1UVw>? MVPJR|UxRTBwMUSg{txO M3zsfFIyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+) Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jZ[lMh|ryP NEfRWVI2KGR? Ml7MSG1UVw>? NInCd2VKSzVyPUCuOVIh|ryP NX;FbWl5OjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+) MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL3N{DPxE1? MlH5OUBl MYfEUXNQ MlzoTWM2OD1yLkG4JO69VQ>? NXPINZBEOjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7tZo4{KM7:TR?= NUjlOohyPSCm MYHEUXNQ NIHEXFZKSzVyPUCuNlch|ryP M333TVIyOjh7Mk[3
Hth7 cells harbored NRAS (Q61R+/−) MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m2RVMh|ryP NFnKVHc2KGR? M{DJV2ROW09? NX7XV3p6UUN3ME20MlUh|ryP NXK5PYp7OjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement NUD6cXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[4N{DPxE1? M2KxdFUh\A>? NV7nepZtTE2VTx?= NYTSVGZQUUN3ME2wMlU6KM7:TR?= M4LlXVIyOjh7Mk[3
Hth74 NX3wTmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj3T4JNOyEQvF2= NIK5b2U2KGR? M2PofmROW09? NHOyS|lKSzVyPUKuNVkh|ryP NXvrUIYyOjF{OEmyOlc>
KAT18 NIXQN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[zJO69VQ>? M2jNPFUh\A>? NHi1R3VFVVOR NWTtSHpXUUN3ME20MlYzKM7:TR?= NH\SPVkzOTJ6OUK2Oy=>
SW1736 NXHq[YVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxNFAh|ryP M1rXUFUh\A>? NXzmT3l6TE2VTx?= NYX1T2ZkUUN3ME20O{42PiEQvF2= MXmyNVI5QTJ4Nx?=
WRO NVW1ZZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyxNVAxOCEQvF2= M4fMO|Uh\A>? MX3EUXNQ MU\JR|UxRjFyMECg{txO MkTSNlEzQDl{Nke=
TAD2 M3K1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnldlNSOTByMDFOwG0> M4jRW|Uh\A>? M2DzWmROW09? M1jDU2lEPTB-MUCwNEDPxE1? NHm4cVAzOTJ6OUK2Oy=>
LN229 MoPDRZBweHSxc3nzJGF{e2G7 Ml3mNE42KM7:TR?= NF\zNG43OCCq NUP0cohoTE2VTx?= NHHGeGtCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= MVyyNlA2PzlzNB?=
T98G NHjYfoZCeG:ydH;zbZMhSXO|YYm= M1H5cFAvPSEQvF2= NY[xN25{PjBiaB?= NWTjeoNCTE2VTx?= NIDTOHZCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= M3TEdFIzODV5OUG0
HC11 M3XkcmZ2dmO2aX;uJGF{e2G7 M1znVlExKM7:TR?= Mo\pNlQhcA>? Mk\MSG1UVw>? M1W0N2lvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> NXzzTnl3OjJ2Mk[2NlE>
MOLT-4 M3XtUGN6fG:2b4jpZ{BCe3OjeR?= MoLZNVAh|ryP NUPhZndqPDhiaB?= MV\EUXNQ NYfQWnFvUUN3ME2xMlfjiIoQvF2= M4\kVFIzPjF2MkSz
CEM-R MoTJR5l1d3SxeHnjJGF{e2G7 NF;zN3oyOCEQvF2= MoDOOFghcA>? MUfEUXNQ Ml60TWM2OD1|LkRihKnPxE1? NWrkdoRUOjJ4MUSyOFM>
CEM-S NFjDOVZEgXSxdH;4bYMhSXO|YYm= MY[xNEDPxE1? Mnn6OFghcA>? MnO2SG1UVw>? MXrJR|UxRTVwMfMAje69VQ>? MXmyNlYyPDJ2Mx?=
MOLT-4 NXfndlU5TnWwY4Tpc44hSXO|YYm= MYGxNEDPxE1? M173dlI1KGh? NFnsZ4xFVVOR MXLCcI9kc3NiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNmKG:oIITo[UBk\WyuIHP5Z4xm M3L5U|IzPjF2MkSz
MOLT-4 M3PoUGZ2dmO2aX;uJGF{e2G7 MYm05qCK|ryP NX7kUXF2PCCq MmX5SG1UVw>? MXTJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> M3XoflIzPjF2MkSz
CEM-R MYLGeY5kfGmxbjDBd5NigQ>? MoKzOQKBkc7:TR?= MoDnOEBp NHrtfoVFVVOR MXPJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNFGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MXeyNlYyPDJ2Mx?=
CEM-S Mli2SpVv[3Srb36gRZN{[Xl? M1jmTVTjiIoQvF2= MonDOEBp NYDyXIJ7TE2VTx?= M4juZ2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M4P1TFIzPjF2MkSz
HepG2 cell MW\LbY5ie2ViQYPzZZk> MnXBNlAh|ryP MlnlNlQhcA>? NELZ[Y1FVVOR MmrvSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? M4HXVlI{Pzl5M{G5
HepG2 cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXtWoFtOzBizszN Ml;uNlQhcA>? Mk\sSG1UVw>? NYXxNJBjUW6qaXLpeJMh[2WubDDndo94fGh? NHzKO2gzOzd7N{OxPS=>
HepG2 cell NYDmPINkSXCxcITvd4l{KEG|c3H5 MYKyNEDPxE1? NYPTSFZJOjRiaB?= M4H5bGROW09? NXzlVo05UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4LINVI{Pzl5M{G5
GEO NUiydZM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q1OlUxOCCwTR?= M4DT[FczKGh? NIL1VlBFVVOR M1TZ[WlvcGmkaYTzJINmdGxiZ4Lve5Rp M{DxPFI1PThzMkOx
CNE-1 NHP1dGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLZNFJyOTBizszN NV65fGx6QTZiaB?= NWW1e41STE2VTx?= NWqzO4ZiUUN3ME2yMlk3KM7:TR?= NGrEN4kzPTN|NkmyOS=>
CNE-2 NGnZ[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX0RppnOTBizszN NF3rRZA6PiCq MYfEUXNQ MULJR|UxRTRwNUOg{txO M4HZOFI2OzN4OUK1
HONE-1 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? M32zTVk3KGh? M3q3cGROW09? MUXJR|UxRTNwM{eg{txO NGLTSYgzPTN|NkmyOS=>
SUNE-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvt[HMyOCEQvF2= M{TLSFk3KGh? NV3odGxMTE2VTx?= M1TwV2lEPTB;MD61NkDPxE1? NX;rNGMxOjV|M{[5NlU>
CNE-2 MXPGeY5kfGmxbjDBd5NigQ>? M3\s[lExKM7:TR?= MV[0PEBp M3vGWGROW09? M12wUWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NIC2cpYzPTN|NkmyOS=>
HONE-1 M2HObWZ2dmO2aX;uJGF{e2G7 MkfQNVAh|ryP NXPHfo03PDhiaB?= MmHWSG1UVw>? MofkTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? MX[yOVM{Pjl{NR?=
NEC8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXXbZRwUUN3ME2wMlA6PjVzIN88US=> MYfTRW5ITVJ?
P12-ICHIKAWA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rVdWlEPTB;MD6xNVYzKM7:TR?= NEP6UWpUSU6JRWK=
MDA-MB-175-VII M4C4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXOTWM2OD1yLkGzO|M5KM7:TR?= MoPrV2FPT0WU
AsPC-1 M13SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP6TWM2OD1yLkKyNVIzKM7:TR?= M4PFT3NCVkeHUh?=
T47D NFL1ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG3XIpTUUN3ME2wMlI5OjVizszN NW\0e3pmW0GQR1XS
HH NUjFfFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjXdoRKSzVyPUCuN|AzQDNizszN NH[xVFNUSU6JRWK=
MOLT-16 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvNWXpKSzVyPUCuN|A{OiEQvF2= M37BN3NCVkeHUh?=
ES5 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr3NZhKSzVyPUCuN|Q1PTVizszN MUXTRW5ITVJ?
RS4-11 M3zHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\vTWM2OD1yLkO0OlEh|ryP NW\weXpJW0GQR1XS
KARPAS-45 M2Xhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwM{ezNlEh|ryP MkXNV2FPT0WU
NCI-H720 M3XCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;rW49KSzVyPUCuN|c3PzlizszN Mmr3V2FPT0WU
H9 NETjTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XQVmlEPTB;MD6zPFg5OyEQvF2= MoDNV2FPT0WU
EFM-19 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TkZmlEPTB;MD60OFAyKM7:TR?= NIGx[4ZUSU6JRWK=
SBC-1 NIPjZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IdnZ1UUN3ME2wMlQ1ODN3IN88US=> M3fkbXNCVkeHUh?=
A4-Fuk NUC5[ZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNE[4Olgh|ryP MmHJV2FPT0WU
NCI-H1563 NELoRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNEixPFkh|ryP NYe2UIRyW0GQR1XS
HCC1419 NEjvWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLoTWM2OD1yLkS4PFkzKM7:TR?= MXTTRW5ITVJ?
H-EMC-SS NXPa[XprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1yLkS5PVM6KM7:TR?= NV7UemZCW0GQR1XS
BHT-101 M1P3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPISHViUUN3ME2wMlUzQTZzIN88US=> NWrxUVhqW0GQR1XS
IGROV-1 NFXXXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHuPHFKSzVyPUCuOVUzPDlizszN NX\NSpVEW0GQR1XS
HGC-27 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHVUpdKSzVyPUCuOVY4QDNizszN NVHNTHV2W0GQR1XS
MDA-MB-361 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNUe3OlEh|ryP NVm2dXMxW0GQR1XS
KE-37 NYG0Oo13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GzN2lEPTB;MD61PFI3KM7:TR?= M2fZcXNCVkeHUh?=
HCC70 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNUm4Nlch|ryP NG\XNplUSU6JRWK=
LNCaP-Clone-FGC M3;o[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PDbGlEPTB;MD62NVA1QCEQvF2= MXjTRW5ITVJ?
HAL-01 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W0[WlEPTB;MD62NlE{KM7:TR?= NWrqO4F5W0GQR1XS
HT M1W0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNkOyN|kh|ryP NEO4V21USU6JRWK=
MDA-MB-415 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNkO2NlYh|ryP NVvWbZpYW0GQR1XS
NOS-1 NF\YZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHTTWM2OD1yLk[zO|I{KM7:TR?= NILl[3NUSU6JRWK=
DU-145 NEDxdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LHN2lEPTB;MD62OFc1PSEQvF2= MWDTRW5ITVJ?
OCUB-M NEflNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPKfmNZUUN3ME2wMlcxQTZ4IN88US=> MkGzV2FPT0WU
VA-ES-BJ M4\3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPWfYRKSzVyPUCuO|MxOjVizszN NYixcYY5W0GQR1XS
J-RT3-T3-5 NVrueHlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHoXoVQUUN3ME2wMlc1PDB|IN88US=> MXnTRW5ITVJ?
MOLT-4 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPtTWM2OD1yLkiwOVgzKM7:TR?= MXTTRW5ITVJ?
NB7 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOEK0NVEh|ryP MUXTRW5ITVJ?
L-363 NUSxNXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7EZZZjUUN3ME2wMlg{PDR{IN88US=> NXHjVnRmW0GQR1XS
NKM-1 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjFOHRUUUN3ME2wMlg3OjV|IN88US=> MWXTRW5ITVJ?
HOP-92 NFnzb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVVWlEPTB;MD64O|IzOyEQvF2= NGf5ZmtUSU6JRWK=
OAW-42 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTRTWM2OD1yLki4O|Ih|ryP MVfTRW5ITVJ?
HuO9 NXTHTFZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLkVFVKSzVyPUCuPVI4PTFizszN NVPTNml6W0GQR1XS
MFE-280 NVe1W2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe5TWM2OD1yLkm2OFY2KM7:TR?= M3r0cHNCVkeHUh?=
EM-2 NI\yVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO4OHNvUUN3ME2wMlk4QTN7IN88US=> NFjvVYNUSU6JRWK=
NCI-H520 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLGRpl2UUN3ME2wMlk5PTl{IN88US=> Ml7mV2FPT0WU
LB2241-RCC NFrTdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwOUm3N|Qh|ryP NXTpOXlEW0GQR1XS
SK-NEP-1 NVywUZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;se5l2UUN3ME2xMlE1PDh3IN88US=> M3P4O3NCVkeHUh?=
LXF-289 NXfKe4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjGTWM2OD1zLkG3NVU3KM7:TR?= NXXXVINQW0GQR1XS
EPLC-272H NHXBdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHEPVZKSzVyPUGuNVczPTZizszN NWr5TYx4W0GQR1XS
COLO-684 NV\JSWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\nXY1FUUN3ME2xMlI{PzJ3IN88US=> MYLTRW5ITVJ?
ES1 NH7le4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrSSHJKSzVyPUGuNlQxPjVizszN Mlu2V2FPT0WU
DOHH-2 NIPJO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzjPJdKSzVyPUGuNlgzODNizszN M3Wye3NCVkeHUh?=
CTB-1 NX;rfYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;m[IhKSzVyPUGuNlg6QSEQvF2= MUfTRW5ITVJ?
G-401 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC2TWM2OD1zLkK5O|k2KM7:TR?= NFn1TW5USU6JRWK=
LoVo MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwM{K1N|Qh|ryP M2jndnNCVkeHUh?=
Ramos-2G6-4C10 NF3iTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Ph[2lEPTB;MT6zN|cxOSEQvF2= MmDGV2FPT0WU
MFM-223 NYS5N5JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHOdXBKSzVyPUGuN|Q1PjFizszN NFTaTodUSU6JRWK=
PA-1 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\IfmlEPTB;MT6zOVI3PSEQvF2= MkXUV2FPT0WU
697 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwM{e2NVYh|ryP MVjTRW5ITVJ?
QIMR-WIL MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TqU2lEPTB;MT60PVEyPiEQvF2= NVz0[3g5W0GQR1XS
HOS NED4SmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwNEm1OVgh|ryP MmCzV2FPT0WU
DMS-273 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHOFJKSzVyPUGuOVE6PTlizszN M4foN3NCVkeHUh?=
ME-180 M{DIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TONGlEPTB;MT61Olg6OSEQvF2= NFL0SVRUSU6JRWK=
HCC2218 NVzJNJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17uZmlEPTB;MT62PFIzPSEQvF2= MUnTRW5ITVJ?
CAL-54 M1Szb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf4XWF2UUN3ME2xMlcyOjR{IN88US=> NGDRcZFUSU6JRWK=
OMC-1 M2CyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwN{S2O|ch|ryP MWXTRW5ITVJ?
COR-L105 M2CxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTVTWM2OD1zLke5O|M4KM7:TR?= MYfTRW5ITVJ?
BV-173 NYfIfXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vvcmlEPTB;MT64NVA4PCEQvF2= M1P1bHNCVkeHUh?=
RKO NHLtR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTxTWM2OD1zLki3NVAyKM7:TR?= NWr1RY1XW0GQR1XS
SNU-387 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwOEi0NFYh|ryP Mmf1V2FPT0WU
SW1088 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i1NWlEPTB;MT65OFYxPiEQvF2= NUnO[Xl6W0GQR1XS
Hs-578-T NF3IU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTy[XhKSzVyPUKuNVE1OzNizszN MXfTRW5ITVJ?
OC-314 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj5TWM2OD1{LkG1NFg3KM7:TR?= M1:5WnNCVkeHUh?=
RMG-I NVrtW5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13jPGlEPTB;Mj6xOlM6QCEQvF2= M4XIXXNCVkeHUh?=
NCI-H1395 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGzSlhKSzVyPUKuNVgxQTFizszN NFjmWI5USU6JRWK=
GAMG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjZR5FsUUN3ME2yMlI{QDR3IN88US=> MVLTRW5ITVJ?
LB1047-RCC M1fiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7lTWM2OD1{LkK0N|E4KM7:TR?= NXz1WYpRW0GQR1XS
MN-60 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwMkm5NlMh|ryP MkXaV2FPT0WU
OAW-28 NXjibnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwMkm5OVEh|ryP NHXkbFVUSU6JRWK=
NCI-H2228 NYPhd5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrkTWM2OD1{LkOxOVUzKM7:TR?= NVf0bWprW0GQR1XS
ABC-1 M{jKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrVTWM2OD1{LkOzNlU{KM7:TR?= MXrTRW5ITVJ?
LS-513 M363d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzVcXVIUUN3ME2yMlM{PDh2IN88US=> NGDVeppUSU6JRWK=
KS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\jNmlEPTB;Mj6zPFE6OSEQvF2= M3rhVHNCVkeHUh?=
NB69 NF7KempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HMZmlEPTB;Mj6zPFk5OyEQvF2= NX7HdlR[W0GQR1XS
VM-CUB-1 M325WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDnepdUUUN3ME2yMlM6ODh|IN88US=> MmfNV2FPT0WU
D-423MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwNEGwOFQh|ryP M4f2T3NCVkeHUh?=
EW-18 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH25OoVKSzVyPUKuOFE6OzlizszN M124d3NCVkeHUh?=
YH-13 NIj6cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73RWpKSzVyPUKuOFYyPTNizszN M{f6eXNCVkeHUh?=
T-24 M1vnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW1TWM2OD1{LkS3PFgyKM7:TR?= MnfmV2FPT0WU
ES8 NH:2NZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfKenhSUUN3ME2yMlQ6Ojh5IN88US=> Mme1V2FPT0WU
ES3 NV7MbZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwNEm3OVkh|ryP MnXTV2FPT0WU
RXF393 NHPzNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLUWpkzUUN3ME2yMlYxPDh5IN88US=> NUfqOW1IW0GQR1XS
RPMI-8226 NUPLZphCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;lWGlEPTB;Mj62Nlk2OyEQvF2= NYj5WpJ{W0GQR1XS
AGS Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe2TWM2OD1{LkeyNVM4KM7:TR?= MlHOV2FPT0WU
HCC1395 NGrSVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLLTWM2OD1{Lke1NVg4KM7:TR?= NVPQW2xmW0GQR1XS
MV-4-11 M{TwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrMUGJzUUN3ME2yMlc2OjZ4IN88US=> MoLTV2FPT0WU
A204 M17DOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojDTWM2OD1{LkizPFczKM7:TR?= M4HIdnNCVkeHUh?=
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XXc2lEPTB;Mj64OlEyPyEQvF2= NGrMZmNUSU6JRWK=
SNU-423 NUCze5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwOEmyOFIh|ryP NGe4VYVUSU6JRWK=
NCI-H1048 M{\O[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXhTWM2OD1{Lkm2PFY2KM7:TR?= MVrTRW5ITVJ?
GR-ST M13IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTKe2dKSzVyPUOuNFQ3OTFizszN M{X1V3NCVkeHUh?=
EoL-1- NXPKbop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzJOnNKSzVyPUOuNFcxPThizszN MlvZV2FPT0WU
HuH-7 M1vMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HTSGlEPTB;Mz6wPVQ3PCEQvF2= MYTTRW5ITVJ?
OS-RC-2 M4Psemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICyWlBKSzVyPUOuNVEyQSEQvF2= NIn5d|FUSU6JRWK=
EW-3 NFjGfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLndWlZUUN3ME2zMlE6PTJ7IN88US=> NGfPNolUSU6JRWK=
NCI-H747 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQTWM2OD1|LkKwOlk1KM7:TR?= MmniV2FPT0WU
EW-16 NHnlb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILBOVJKSzVyPUOuNlE5PzlizszN NG\ESotUSU6JRWK=
DOK NUnJc|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEWFhKSzVyPUOuNlI5PTlizszN NXHTSYFCW0GQR1XS
HCC2157 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzPTm12UUN3ME2zMlM5OTd7IN88US=> Mm[wV2FPT0WU
OVCAR-3 NGDOdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNwNEC3PFYh|ryP NXHCXFlEW0GQR1XS
NCI-H1623 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HvSGlEPTB;Mz60NVIzPCEQvF2= MYnTRW5ITVJ?
H4 NXe0[nBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnTWM2OD1|LkS1OlI3KM7:TR?= Mn;EV2FPT0WU
SW1710 NWDtOY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwNE[2O|gh|ryP M2X4OnNCVkeHUh?=
RT-112 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHsTZJsUUN3ME2zMlUzOzh6IN88US=> MVnTRW5ITVJ?
DMS-114 NHzGRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWTWM2OD1|Lk[yNlc5KM7:TR?= M1\1fXNCVkeHUh?=
AN3-CA MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnWVYdKSzVyPUOuOlI1PTZizszN NYjWPHFGW0GQR1XS
KNS-62 NUPEfZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzaTWM2OD1|Lk[zN|M5KM7:TR?= NVfqPGxWW0GQR1XS
SJRH30 M3zlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDjTWM2OD1|Lk[5NVIzKM7:TR?= M{HoNHNCVkeHUh?=
G-402 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OWXFHUUN3ME2zMlcxPzFzIN88US=> NWDOV3hjW0GQR1XS
MHH-PREB-1 NIXMbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDTbo9CUUN3ME2zMlczODN6IN88US=> MXnTRW5ITVJ?
P30-OHK M3X2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOzSlY3UUN3ME2zMlgxQTd4IN88US=> NFTlOFZUSU6JRWK=
RVH-421 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDLW2JpUUN3ME2zMlgyPzh6IN88US=> M3K3[nNCVkeHUh?=
LU-134-A NV7qXZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnaOINKSzVyPUOuPFg1OjhizszN NV3YU|BQW0GQR1XS
ECC10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwOUO2NlIh|ryP NH\6e|RUSU6JRWK=
TGW NYXSTVhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LnRmlEPTB;ND6wNlMxPSEQvF2= MYrTRW5ITVJ?
MLMA MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O5WWlEPTB;ND6wNlk3PiEQvF2= NGnNR2lUSU6JRWK=
SCC-25 M{jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRwME[1OlYh|ryP NVzJcZl1W0GQR1XS
TYK-nu M1jRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XTfmlEPTB;ND6wPVU{PCEQvF2= NFLmOJNUSU6JRWK=
LAMA-84 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwMUSxPVEh|ryP MkjtV2FPT0WU
Calu-3 NILsTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwRWlEPTB;ND6yOFQyPiEQvF2= NE\OW|ZUSU6JRWK=
NCI-H460 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfOXZFnUUN3ME20MlI3PDR|IN88US=> NVi2[JpzW0GQR1XS
EGI-1 NV7pdYxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHTUpZ{UUN3ME20MlM4Pzd6IN88US=> MWLTRW5ITVJ?
NCI-H292 NETvVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRwM{ixOFYh|ryP NIHad4xUSU6JRWK=
HCE-T NGPidYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXPTWM2OD12LkSxOVc6KM7:TR?= NILkZnlUSU6JRWK=
EW-11 NUjxTnp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRwNEG4N|gh|ryP NECxcmRUSU6JRWK=
ATN-1 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRwNESzNFQh|ryP NX6xPZhpW0GQR1XS
NB5 NHj5NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHNTWM2OD12LkWzOlk4KM7:TR?= NWnmR5VFW0GQR1XS
KLE MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRwN{CxPVgh|ryP NWr3eVNCW0GQR1XS
CAL-39 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn63TWM2OD12LkeyNVQ3KM7:TR?= M{jQbnNCVkeHUh?=
TI-73 M3\CTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwOEC2NFkh|ryP NWiwcGRLW0GQR1XS
HO-1-N-1 NUDGTIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwOUSyJO69VQ>? NUTvfG9lW0GQR1XS
786-0 M{jDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7jZ3NKSzVyPUSuPVQ3PzNizszN M{LrOXNCVkeHUh?=
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwOU[xOFIh|ryP MWHTRW5ITVJ?
NCI-H446 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHrT|dKSzVyPUWuNlAxODlizszN MmXzV2FPT0WU
ETK-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfYc3FbUUN3ME21MlIyOTZ3IN88US=> NX7jepRbW0GQR1XS
BT-20 NGq0RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTVwMkGzOVMh|ryP M3TkcHNCVkeHUh?=
MEL-HO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\HTWM2OD13LkO3N|M3KM7:TR?= Mlr0V2FPT0WU
CAL-27 NHu1SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjJeoJmUUN3ME21MlQ3OzN7IN88US=> MlrKV2FPT0WU
SW872 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ftWWlEPTB;NT61PVQzQCEQvF2= NFPMVVNUSU6JRWK=
RPMI-2650 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETWNWNKSzVyPUWuOlYyQTlizszN MXzTRW5ITVJ?
PFSK-1 NHPifY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TYZ2lEPTB;NT63Nlc{OiEQvF2= NEnXdZpUSU6JRWK=
SF295 NYTkT5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LvTmlEPTB;NT64NFY{OyEQvF2= MojRV2FPT0WU
Becker M{Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnvdXVKSzVyPUWuPFY1PzJizszN M4q0bXNCVkeHUh?=
Saos-2 NIf4VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f3[mlEPTB;NT64OlU{KM7:TR?= MnPHV2FPT0WU
SK-OV-3 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\NXINRUUN3ME21Mlk6QDF4IN88US=> M3XVUXNCVkeHUh?=
VMRC-RCZ MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHHRpluUUN3ME22MlA5Pzd|IN88US=> NYTCSJFzW0GQR1XS
EW-22 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6dWlEPTB;Nj6xPVY1QSEQvF2= MXTTRW5ITVJ?
BT-474 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rsU2lEPTB;Nj6yN|Mh|ryP MnLNV2FPT0WU
BFTC-909 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj0c2pOUUN3ME22MlMxOzR3IN88US=> MV7TRW5ITVJ?
NB12 M3TIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TDfmlEPTB;Nj6zPVA4OSEQvF2= MmTFV2FPT0WU
D-263MG M3zJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrqfFNKSzVyPU[uOFUyPjlizszN MVPTRW5ITVJ?
SNB75 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Xb2FKSzVyPU[uOlAyPDNizszN NYq2WmQzW0GQR1XS
A704 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkTWM2OD14Lk[zNFYh|ryP MnjXV2FPT0WU
NCI-H1693 M1u1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf3TWM2OD14Lk[zOlA1KM7:TR?= MV\TRW5ITVJ?
LN-405 M2jX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD14Lke5OlczKM7:TR?= MUXTRW5ITVJ?
CHL-1 NGjoW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\kTWM2OD14LkiwNFc6KM7:TR?= MlrjV2FPT0WU
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTZwOEG5OlEh|ryP NWjsdXFmW0GQR1XS
TE-12 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r0UGlEPTB;Nj64N|gyPyEQvF2= MoDkV2FPT0WU
TE-6 NVyxVHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\QUVZKSzVyPU[uPVMxOzhizszN NVLMc4dNW0GQR1XS
AU565 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPT3JKSzVyPU[uPVY6PTdizszN M2j0R3NCVkeHUh?=
RD Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vT5JKSzVyPU[uPVgzQDRizszN NVj6XpN7W0GQR1XS
SW1463 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjFTWM2OD15LkGxNVY5KM7:TR?= M2O4fHNCVkeHUh?=
LU-99A NWTUU|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PyTGlEPTB;Nz6xOFMzOiEQvF2= MmfvV2FPT0WU
NCI-H28 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnzdnppUUN3ME23MlI6OjRizszN NXf0UnhEW0GQR1XS
MC-IXC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrrNI9KSzVyPUeuOFg2PzZizszN MnXGV2FPT0WU
GP5d M4PGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGzTWM2OD15LkS4O|Y1KM7:TR?= MmPaV2FPT0WU
GB-1 M2DZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{frU2lEPTB;Nz61OFgxPCEQvF2= MnrOV2FPT0WU
CAL-33 M1PYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXnTZJIUUN3ME23MlY3OjN|IN88US=> NUm1S4R2W0GQR1XS
MSTO-211H NGH4SFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS4VIlKSzVyPUeuOlc{OzZizszN MW\TRW5ITVJ?
TE-5 M1i3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTdwN{mzN|Qh|ryP M1L1enNCVkeHUh?=
D-566MG NHn3SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuNGlEPTB;OD6wOFQzQSEQvF2= Mlu2V2FPT0WU
JVM-3 M4rRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRThwMUWyOlgh|ryP NYj6S|ZtW0GQR1XS
T98G MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfqXFA5UUN3ME24MlE5ODZ5IN88US=> NYm1N|JlW0GQR1XS
HCC1954 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInMOIhKSzVyPUiuOFUyODRizszN NH3uZYhUSU6JRWK=
SF126 M1vVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjYTHBNUUN3ME24MlQ2QTN4IN88US=> NYrUPIFEW0GQR1XS
LB996-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrXUWNKSzVyPUiuOVMzPTdizszN NUjlcnBiW0GQR1XS
SKG-IIIa NETG[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HiXGlEPTB;OD62N|A3QSEQvF2= NHXZZYlUSU6JRWK=
NCI-SNU-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMdYNGUUN3ME24MlY1PjR|IN88US=> MnrvV2FPT0WU
LB771-HNC NGP4bHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DtbWlEPTB;OD62OFY6PiEQvF2= MX7TRW5ITVJ?
SCC-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jhRWlEPTB;OD62PFIyQSEQvF2= MoL2V2FPT0WU
CAMA-1 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vxdmlEPTB;OD63O|E1PiEQvF2= MoexV2FPT0WU
D-502MG MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrXe2d4UUN3ME24Mlc5PjJ7IN88US=> MWDTRW5ITVJ?
ESS-1 NYTqVlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWzTWM2OD16Lki4O|A1KM7:TR?= M130OXNCVkeHUh?=
HEC-1 NX;ySnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiXpJKSzVyPUiuPFk5PjZizszN NIKzRmVUSU6JRWK=
NB10 NGrVR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonhTWM2OD17LkCyNlI1KM7:TR?= NWDleXFjW0GQR1XS
8505C MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:1XJpKSzVyPUmuNFQzOzJizszN Mkn5V2FPT0WU
EFO-27 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m0[GlEPTB;OT6xOlQyOiEQvF2= NUns[ZY{W0GQR1XS
HN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTlwMU[2Nlgh|ryP M4n2S3NCVkeHUh?=
DSH1 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX62dWdWUUN3ME25MlIxQDdizszN M1HTVXNCVkeHUh?=
NBsusSR M3r4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITsNHdKSzVyPUmuNlc1ODJizszN NXLGXY92W0GQR1XS
LS-123 NE\K[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD17LkOxO|YyKM7:TR?= NFHrO|VUSU6JRWK=
SHP-77 M4SwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;N[WNKSzVyPUmuN|k6OzVizszN M2nwVXNCVkeHUh?=
ACN Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTlwNUOyO|ch|ryP M3nhPXNCVkeHUh?=
U251 M1\rZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPrfVBKSzVyPUmuOlU2PDRizszN NFruNFlUSU6JRWK=
A431 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ewfmlEPTB;OT64NFI{QCEQvF2= NH;4R5lUSU6JRWK=
5637 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHJVItKSzVyPUmuPFQ6QDRizszN MXjTRW5ITVJ?
MDA-MB-157 M2XQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHrNpFKSzVyPUmuPVI5PzhizszN MUHTRW5ITVJ?
A101D NUHCRVJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33NZ2lEPTB;OT65PVk4PCEQvF2= MlXtV2FPT0WU
YKG-1 M{LQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFyLkKwNFYh|ryP MlXNV2FPT0WU
LAN-6 NV6zOJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfk[lZNUUN3ME2xNE4zOTZ2IN88US=> MV\TRW5ITVJ?
OVCAR-5 NX24SHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO5TWM2OD1zMD6yOFM{KM7:TR?= MlfpV2FPT0WU
A549 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aN3pKSzVyPUGwMlM6PzNizszN M{XjbHNCVkeHUh?=
no-11 NUDKNVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1zMD60N|U{KM7:TR?= MVXTRW5ITVJ?
SF539 NYHv[FdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPkeZNKSzVyPUGwMlkxPDFizszN M4iyfXNCVkeHUh?=
A388 M{PUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDsTWM2OD1zMT6zPFk4KM7:TR?= Ml3GV2FPT0WU
DEL M2jrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXQOWNbUUN3ME2xNU41OjRizszN NFy3W5hUSU6JRWK=
SW954 NYLoTnBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFzLkS2Olgh|ryP NV;W[nV2W0GQR1XS
TK10 NYraPZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrpSY1qUUN3ME2xNU42OjdzIN88US=> NV3VdHJoW0GQR1XS
SW756 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13EVmlEPTB;MUGuOVI6PCEQvF2= MmLxV2FPT0WU
PC-3 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPROm1CUUN3ME2xNU42PzZ2IN88US=> NUflZm5DW0GQR1XS
ONS-76 NHrBZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFzLk[zOkDPxE1? NVLqVGRNW0GQR1XS
A427 NYL3R41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH3O5VkUUN3ME2xNU44ODl|IN88US=> MUPTRW5ITVJ?
MEG-01 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm1RVFGUUN3ME2xNU44PTB7IN88US=> NHzC[pVUSU6JRWK=
BB30-HNC NH\mVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzO5FWUUN3ME2xNU44QTh{IN88US=> M{f5e3NCVkeHUh?=
NCI-H1299 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\zNGlEPTB;MUGuPFA6OyEQvF2= MkPCV2FPT0WU
GCT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFzLkiyNlgh|ryP NVOxUXIyW0GQR1XS
D-247MG MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfhemFKSzVyPUGxMlk3PjNizszN NHvaXYZUSU6JRWK=
CFPAC-1 NIiyNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfpTWM2OD1zMT65O|gzKM7:TR?= NXjDbpNTW0GQR1XS
EKVX MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXIc5pKSzVyPUGyMlA{OTNizszN MVvTRW5ITVJ?
CAL-51 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnoNVdwUUN3ME2xNk4xPzF4IN88US=> NG\IV3ZUSU6JRWK=
BB49-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrpOJZbUUN3ME2xNk4yOTd5IN88US=> NEfpd|lUSU6JRWK=
RPMI-7951 M{excmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnflTWM2OD1zMj6xPFU1KM7:TR?= NEPFU29USU6JRWK=
RH-1 NWjEWYtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLU3RyUUN3ME2xNk4zOTh2IN88US=> Mo\yV2FPT0WU
BCPAP MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z5bGlEPTB;MUKuOFc1QSEQvF2= NUjxeGRqW0GQR1XS
GCIY MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvIOVBrUUN3ME2xNk42OjB7IN88US=> MXXTRW5ITVJ?
KNS-81-FD NYnNTY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPFeXBjUUN3ME2xNk42QDZ7IN88US=> NY\5eoV{W0GQR1XS
KYSE-140 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLyTWM2OD1zMj64OVk2KM7:TR?= MUPTRW5ITVJ?
Ca-Ski M1S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\OTWM2OD1zMj65NFQyKM7:TR?= MYnTRW5ITVJ?
TGBC1TKB Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPTeFNnUUN3ME2xNk46OTF3IN88US=> M3qybHNCVkeHUh?=
HCC1187 M4\tbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF|LkG5NVIh|ryP NELmSHpUSU6JRWK=
SJSA-1 M2X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF|LkKzNlch|ryP NV7qU3d{W0GQR1XS
CTV-1 M4DGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfqRXpSUUN3ME2xN{4{PDVizszN MmXSV2FPT0WU
WM-115 M1;LOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrqR5AzUUN3ME2xN{43PDh|IN88US=> NWO2dWxNW0GQR1XS
CHP-212 NUTIPVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXqTWM2OD1zMz65O|M6KM7:TR?= NXLGPG5qW0GQR1XS
SCC-15 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv3Z49KSzVyPUGzMlk4PzVizszN NXv6clVyW0GQR1XS
BPH-1 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTtVJFKSzVyPUG0MlE3PjRizszN M1fyW3NCVkeHUh?=
SW780 M2LOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnvTWM2OD1zND61NFI2KM7:TR?= Mnf5V2FPT0WU
NCI-H2291 NHr3fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF2LkW4O|gh|ryP M1TFSXNCVkeHUh?=
JEG-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D6NGlEPTB;MUSuOlMzPiEQvF2= NYTSZmpsW0GQR1XS
CAL-120 NGjL[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjJc3J7UUN3ME2xOE44ODJ5IN88US=> NH;BfplUSU6JRWK=
NCI-H23 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW0UXFuUUN3ME2xOE44QTl5IN88US=> MVrTRW5ITVJ?
MS-1 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\wTWM2OD1zND65OlEyKM7:TR?= Mle3V2FPT0WU
PC-14 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\XcGlEPTB;MUSuPVY2PCEQvF2= NIqwfYhUSU6JRWK=
D-283MED MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3PfYNCUUN3ME2xOU4xOTFzIN88US=> NXy1[ldqW0GQR1XS
OE19 M{XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml62TWM2OD1zNT6xOVQyKM7:TR?= NUO5SmQ4W0GQR1XS
CAS-1 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1zNT60NVg1KM7:TR?= MoLHV2FPT0WU
NCI-H727 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDWfGhOUUN3ME2xOU41OjJzIN88US=> NWHCUG9VW0GQR1XS
SiHa MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF3Lke1PVQh|ryP NFXTSZNUSU6JRWK=
BFTC-905 NIq5eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXVGlEPTB;MUWuO|Y6PCEQvF2= MVjTRW5ITVJ?
MDA-MB-453 M3;lWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzIOoFJUUN3ME2xOk4yPjR{IN88US=> MUTTRW5ITVJ?
HuP-T3 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTZU49KSzVyPUG2MlY{PzNizszN NYPJU|VWW0GQR1XS
SK-LU-1 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITOdGNKSzVyPUG2MlY6PTZizszN NFfWWHRUSU6JRWK=
Detroit562 M4Lqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO0TWM2OD1zNj63N|E5KM7:TR?= MX\TRW5ITVJ?
HCC1569 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\2TWM2OD1zNj64N|M4KM7:TR?= MV3TRW5ITVJ?
SK-MES-1 M2HH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPKe2FKSzVyPUG2Mlg1OTlizszN NWHmNYpkW0GQR1XS
BB65-RCC M4Hmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qwOmlEPTB;MUeuNFQ4QSEQvF2= M2n3dHNCVkeHUh?=
LOXIMVI NEHJTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPxZ4FKSzVyPUG3MlA4ODdizszN M2PWOXNCVkeHUh?=
SW1783 NUO0SY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2iycWlEPTB;MUeuNVI5KM7:TR?= M2H4cHNCVkeHUh?=
NH-12 NFzl[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLITWM2OD1zNz6zN|A{KM7:TR?= M3PYNnNCVkeHUh?=
UACC-257 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnDWoFRUUN3ME2xO{42PTF{IN88US=> NH;nSJBUSU6JRWK=
KOSC-2 M2jXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TMXWlEPTB;MUeuOlc2PyEQvF2= MmLCV2FPT0WU
KG-1 M3HaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF5Lk[5N|ch|ryP M4TMVHNCVkeHUh?=
M059J M1XJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO1TWM2OD1zNz63NFMh|ryP MXLTRW5ITVJ?
MHH-NB-11 M13HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF5Lkm2O|Mh|ryP NVXJXnVQW0GQR1XS
EW-1 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF6LkGzPFIh|ryP MlXlV2FPT0WU
CAL-85-1 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF6LkKzOVch|ryP MlHqV2FPT0WU
639-V MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzmTWM2OD1zOD6zN|U1KM7:TR?= MXfTRW5ITVJ?
C32 MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTDRllKSzVyPUG4MlQ4OjdizszN NY\LNGk2W0GQR1XS
KM-H2 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF6LkWyN|Ih|ryP MX;TRW5ITVJ?
A253 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvpSWpKSzVyPUG4MlczQDZizszN M1\pO3NCVkeHUh?=
NCI-N87 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHPOVRKSzVyPUG4MlkxODhizszN MlnlV2FPT0WU
8-MG-BA Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS4OXYzUUN3ME2xPU4xPjR4IN88US=> NES5PXJUSU6JRWK=
GI-ME-N MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP5TWM2OD1zOT6xOVQ3KM7:TR?= MYnTRW5ITVJ?
8305C MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT4TWM2OD1zOT6yNlg3KM7:TR?= MkH2V2FPT0WU
TE-8 NWPtZWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXsSXUzUUN3ME2xPU4{ODJ2IN88US=> NUWzXXNTW0GQR1XS
KYSE-270 NWrP[41TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\HfohTUUN3ME2yNE4xOjF5IN88US=> NHfMV3JUSU6JRWK=
HL-60 NXzzd5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLkC5OFEh|ryP NUG2cFU5W0GQR1XS
Mo-T M1;pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j6ZmlEPTB;MkCuNVY3PSEQvF2= NIjROG9USU6JRWK=
NCI-H1355 NGXtTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj6Z5M4UUN3ME2yNE4{Ozd2IN88US=> MYnTRW5ITVJ?
HT-1080 NI\mTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzTWM2OD1{MD61OFk4KM7:TR?= NVvGcY14W0GQR1XS
MIA-PaCa-2 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLv[5NUUUN3ME2yNE43QDh|IN88US=> NGLFN25USU6JRWK=
NCI-H441 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT6eIRKSzVyPUKwMlc{PzlizszN NHTHVFhUSU6JRWK=
LCLC-97TM1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfzfW9KSzVyPUKwMlgyOzRizszN MkDGV2FPT0WU
HT-3 NXzPcm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTO4hQUUN3ME2yNU42PjNzIN88US=> NVHsNY8zW0GQR1XS
22RV1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfl[pZIUUN3ME2yNU42Pjh3IN88US=> NGjzb2JUSU6JRWK=
LK-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZZok{UUN3ME2yNU42QTV|IN88US=> MVvTRW5ITVJ?
CW-2 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHyTWM2OD1{MT62NFY6KM7:TR?= MV\TRW5ITVJ?
KYSE-510 NFvIOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJzLk[wPVUh|ryP MULTRW5ITVJ?
CGTH-W-1 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJzLkexOlYh|ryP NIXMdHFUSU6JRWK=
NCI-H661 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ{LkCzOEDPxE1? NX6wPGJCW0GQR1XS
KU-19-19 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fJfWlEPTB;MkKuNVY6PyEQvF2= M3rhSnNCVkeHUh?=
NCI-H2122 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ{LkK0N|Ih|ryP M4j0XXNCVkeHUh?=
NCI-H526 NETDOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wemlEPTB;MkKuN|g6PSEQvF2= MXXTRW5ITVJ?
NCI-H1650 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ{Lke2OEDPxE1? M4LiO3NCVkeHUh?=
AM-38 NXHidXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPvSmtnUUN3ME2yNk45Pjh7IN88US=> MmTvV2FPT0WU
NCI-H2405 M3vrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfyXFB3UUN3ME2yN{4zPTN|IN88US=> NH3DPYRUSU6JRWK=
M14 M1PjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXzXFN1UUN3ME2yN{41ODh6IN88US=> MnrBV2FPT0WU
ES4 NYLD[IpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXFSmRKSzVyPUKzMlQzOzJizszN M2WwOXNCVkeHUh?=
DJM-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4VGlEPTB;MkOuOVI{PCEQvF2= MYLTRW5ITVJ?
S-117 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nHRWlEPTB;MkOuO|Y2OSEQvF2= Mnf5V2FPT0WU
MZ2-MEL NXLKfmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfQTWM2OD1{Mz63O|U6KM7:TR?= NGLaVpVUSU6JRWK=
SK-MEL-2 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfBTWM2OD1{Mz64NVM{KM7:TR?= MXjTRW5ITVJ?
HCC1806 NYnIPVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rmcWlEPTB;MkOuPFcxQSEQvF2= NUjEVnE4W0GQR1XS
NMC-G1 NIjvc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzETWM2OD1{ND6yNlI3KM7:TR?= MkOyV2FPT0WU
DK-MG NH3mU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ2LkK5OEDPxE1? MWDTRW5ITVJ?
SK-N-FI MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrPOmt2UUN3ME2yOE4{OzB{IN88US=> NU\QZ2x2W0GQR1XS
KINGS-1 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj4TWM2OD1{ND60PFc1KM7:TR?= Mmm5V2FPT0WU
HCC2998 NX:3VIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi4bldKSzVyPUK0MlQ5QDVizszN M2jLW3NCVkeHUh?=
ALL-PO NGDod25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ2Lk[xPUDPxE1? M3;lZnNCVkeHUh?=
MPP-89 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2zXXhKSzVyPUK1MlA1PThizszN NX;ZOFFnW0GQR1XS
NCI-H2342 M3rxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ3LkG5OVMh|ryP M4LNb3NCVkeHUh?=
TE-1 M2DM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkTWM2OD1{NT6zOVY{KM7:TR?= MnzDV2FPT0WU
RH-18 M4HUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfTTWM2OD1{NT61PVE5KM7:TR?= M4XpXXNCVkeHUh?=
HT-1376 M4LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLVTWM2OD1{NT62OFY2KM7:TR?= NF:5ZlNUSU6JRWK=
U-2-OS NIHTe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHYNoFKSzVyPUK1MlY5QDhizszN NWDNdWFIW0GQR1XS
BT-549 NIjqb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fNeWlEPTB;MkWuPVAyOSEQvF2= M2DFenNCVkeHUh?=
NCI-H1755 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\zXWlEPTB;MkWuPVk1PSEQvF2= NIPR[FFUSU6JRWK=
EW-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDETWM2OD1{Nj6wNlc1KM7:TR?= NYTRd5lIW0GQR1XS
NB13 NWrlPXNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jXcWlEPTB;Mk[uNFk1QSEQvF2= MmfzV2FPT0WU
NUGC-3 NELyUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNW29KSzVyPUK2MlIyODNizszN M4PaOHNCVkeHUh?=
GMS-10 NXrW[4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNbWlEPTB;Mk[uNlM2OyEQvF2= MUjTRW5ITVJ?
CHP-134 NHj5UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu2XnRKSzVyPUK2MlM5PjdizszN MVPTRW5ITVJ?
SW962 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\NcopjUUN3ME2yOk42ODJzIN88US=> NGTuTpFUSU6JRWK=
SNU-449 M1TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O5cmlEPTB;MkeuNFgxOyEQvF2= NECySolUSU6JRWK=
HuP-T4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGxTWM2OD1{Nz6wPFc6KM7:TR?= MYnTRW5ITVJ?
SW948 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPabYxnUUN3ME2yO{4yOzR2IN88US=> NEHMXVNUSU6JRWK=
NCI-H226 M1vxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ5LkS1O|gh|ryP NWjYTFBiW0GQR1XS
SK-PN-DW NYTJVWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TJ[WlEPTB;MkeuOlAyOiEQvF2= M3fFW3NCVkeHUh?=
GI-1 NFPtPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvJTWM2OD1{Nz63NlEh|ryP MofXV2FPT0WU
CAL-12T M3T0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ6LkGxNVIh|ryP MVPTRW5ITVJ?
YAPC M{joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ6LkK1OlQh|ryP NX3ZXldQW0GQR1XS
SNU-C2B MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\QSJRKSzVyPUK4MlI6PjRizszN MmHFV2FPT0WU
RCC10RGB MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYS3piUUN3ME2yPE42PDF5IN88US=> MkHpV2FPT0WU
ES7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ7LkG0OlUh|ryP MULTRW5ITVJ?
PANC-03-27 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fWemlEPTB;MkmuOFQ1KM7:TR?= NFHvPGJUSU6JRWK=
ES6 NHLic3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP5fFVKSzVyPUK5MlgyPTdizszN NEnuUYlUSU6JRWK=
HT-1197 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNyLkC1PVgh|ryP NF21V2FUSU6JRWK=
ZR-75-30 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNyLkKzPFMh|ryP MYHTRW5ITVJ?
DB MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQN2wyUUN3ME2zNE41QTR{IN88US=> MmX3V2FPT0WU
OCI-AML2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\lW5hvUUN3ME2zNU4xPjlizszN Mm\1V2FPT0WU
NCI-H2170 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNzLki1NVYh|ryP MnPEV2FPT0WU
IST-MES1 M3Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN{LkK4PVch|ryP MXPTRW5ITVJ?
769-P NYDSW25HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTP[ZhFUUN3ME2zNk4{PjRzIN88US=> MYHTRW5ITVJ?
COR-L23 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\2cGlEPTB;M{KuPVA4OyEQvF2= MWTTRW5ITVJ?
SW626 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\xRmlEPTB;M{OuNVc4PiEQvF2= NGf6eoJUSU6JRWK=
LU-139 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H0ZWlEPTB;M{OuOlYxPSEQvF2= M2DneXNCVkeHUh?=
HT-144 M1v6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN|Lki2N{DPxE1? NF\WS25USU6JRWK=
CaR-1 M4fGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[2ZmVKSzVyPUOzMlk5OjJizszN NWnMepI4W0GQR1XS
OE33 NHXZZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzqU2lzUUN3ME2zOE4zQDV3IN88US=> MXLTRW5ITVJ?
COLO-800 M2XVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN2LkO2OFch|ryP NYWzc2JoW0GQR1XS
NB14 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN2LkS2PFQh|ryP NHj4fGZUSU6JRWK=
KURAMOCHI MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DFPWlEPTB;M{[uNVE6QCEQvF2= M2jXeHNCVkeHUh?=
SW48 NHT2OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf0TWM2OD1|Nj6yOFc1KM7:TR?= NXHDXGVIW0GQR1XS
Daoy MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofuTWM2OD1|Nj62OVM5KM7:TR?= MWjTRW5ITVJ?
TGBC24TKB NInCOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nocmlEPTB;M{[uOlch|ryP MVnTRW5ITVJ?
DU-4475 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jfWlEPTB;M{[uPVA{OyEQvF2= NFnM[oxUSU6JRWK=
SW1417 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XmcmlEPTB;M{iuNFU2OiEQvF2= MWrTRW5ITVJ?
EFO-21 M3HGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3pZoNkUUN3ME2zPE46OzR7IN88US=> NYTRXJhGW0GQR1XS
MG-63 NH\UOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN7LkO0NlQh|ryP NIjOfG9USU6JRWK=
LC-2-ad NWj1SmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHLTWM2OD1|OT61OVEzKM7:TR?= NE\aN|lUSU6JRWK=
NOMO-1 NIm0N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfCTWM2OD1|OT64Nlc1KM7:TR?= MXLTRW5ITVJ?
COLO-741 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q2dWlEPTB;NECuNVMxPCEQvF2= Mn3QV2FPT0WU
BxPC-3 NWm5NJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\VTWM2OD12MD61Olg3KM7:TR?= NUex[pdpW0GQR1XS
HSC-2 NXPaW|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\EbFhKSzVyPUSwMlkyOTNizszN NHW4V4ZUSU6JRWK=
UMC-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvFc4RFUUN3ME20NU4zPjNizszN Mo\kV2FPT0WU
HCC1937 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vR2lEPTB;NEKuO|g1OyEQvF2= MUfTRW5ITVJ?
Calu-6 NWjMOlE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnzT3FKSzVyPUSzMlI{QDJizszN M2nzenNCVkeHUh?=
NCI-H1573 NXPldZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHLTpNKSzVyPUSzMlM1PzdizszN NHPI[JZUSU6JRWK=
SK-N-AS MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLydolmUUN3ME20N{43ODF7IN88US=> NH\XRZVUSU6JRWK=
PSN1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzaTWM2OD12NT6yOVQ5KM7:TR?= MUjTRW5ITVJ?
TE-11 M{jZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu4UGNKSzVyPUS1MlQ5PDJizszN NFSzcGNUSU6JRWK=
NCI-H1155 M1Wy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XyPWlEPTB;NEWuPFk3PyEQvF2= M4jxd3NCVkeHUh?=
KM12 NUPPbZl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWWopKSzVyPUS1MlkxPzZizszN MkLGV2FPT0WU
RO82-W-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[2c|hRUUN3ME20Ok46QDJ{IN88US=> M3TSTnNCVkeHUh?=
SW1573 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\BTWM2OD12Nz6zO|M3KM7:TR?= MkTlV2FPT0WU
CAKI-1 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD12OD6yPFQ2KM7:TR?= M1GwPXNCVkeHUh?=
U-118-MG M4\ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHxTWM2OD12OD6zO|AzKM7:TR?= M3;jbnNCVkeHUh?=
KYSE-520 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5TWM2OD12OD60NFE3KM7:TR?= NGDxdZlUSU6JRWK=
HT55 NYL0ZnFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\wTWM2OD12OT6xOFc1KM7:TR?= NFXaPYZUSU6JRWK=
ChaGo-K-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxToozUUN3ME20PU41Pzl|IN88US=> NXTmXZNKW0GQR1XS
IA-LM NF7YfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqwVVhKSzVyPUW0MlY{OjJizszN NUTybGc2W0GQR1XS
UACC-62 NFzZ[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPMSYNKSzVyPUW1MlExPDZizszN NEC0RYxUSU6JRWK=
MKN7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\MNXZ3UUN3ME21Ok4xOjh3IN88US=> MkP0V2FPT0WU
HPAF-II MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TXSWlEPTB;NU[uOFA4OyEQvF2= NXHGR3NUW0GQR1XS
NTERA-S-cl-D1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPyNGtKSzVyPUW3Mlc4QCEQvF2= NIfNT3BUSU6JRWK=
FTC-133 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvPOlNKSzVyPUW4MlA6PjlizszN NVrkWWRRW0GQR1XS
MHH-ES-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nNVGlEPTB;NUiuOFgyPCEQvF2= MoD2V2FPT0WU
JVM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LDdWlEPTB;NUiuPVUxPiEQvF2= MUjTRW5ITVJ?
TCCSUP MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XQTmlEPTB;NUmuOVI4QSEQvF2= NVzRSVd5W0GQR1XS
COLO-824 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLwTWM2OD14MD6wO|E6KM7:TR?= MmP3V2FPT0WU
647-V NHXXdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLLTWM2OD14MD6xN|Q4KM7:TR?= MkDXV2FPT0WU
HD-MY-Z NEX0[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHzVGFKSzVyPU[wMlUzQTRizszN MmHRV2FPT0WU
LS-411N NUXjXW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzjTWM2OD14MT6zPVA{KM7:TR?= NF\4VXdUSU6JRWK=
NCI-H596 M3TOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jsU2lEPTB;NkKuO|Q6PiEQvF2= M{LGOnNCVkeHUh?=
C-33-A NX7zdpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOwTWM2OD14ND6wPVU4KM7:TR?= NV3kOXJVW0GQR1XS
BHY Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj5TWM2OD14ND6xNlQ2KM7:TR?= NGOy[GRUSU6JRWK=
KGN MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfLeoJ2UUN3ME22OE42PTF2IN88US=> NIXpVJlUSU6JRWK=
NCI-H1092 NFq3SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HsOmlEPTB;NkWuNFA6PSEQvF2= M1HieXNCVkeHUh?=
MZ1-PC M3SwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjCTWM2OD14NT61OlQ6KM7:TR?= NHrFcnRUSU6JRWK=
LB831-BLC M2CwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXLWW85UUN3ME22OU45PDhzIN88US=> M4HL[3NCVkeHUh?=
SW620 M2q1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvNT|lKSzVyPU[2MlIxOzlizszN M1vZVHNCVkeHUh?=
HuO-3N1 NEjJT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrjNm1DUUN3ME22PE4{OjN6IN88US=> Mlz3V2FPT0WU
SK-HEP-1 NH\Wd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTZ7Lkm0PFYh|ryP M2SzNnNCVkeHUh?=
LCLC-103H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjITWM2OD15MD62O|A2KM7:TR?= MU\TRW5ITVJ?
KYSE-70 M1K0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;JTWM2OD15MD63PFM2KM7:TR?= NWDMNFM4W0GQR1XS
Mewo NVvRVohpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdzLkWwOUDPxE1? NFOxNJdUSU6JRWK=
COLO-668 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdzLki0OVEh|ryP NInn[W5USU6JRWK=
NCI-H522 M3\mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXiNGxKSzVyPUeyMlM1OTNizszN NGrkd|dUSU6JRWK=
NCI-H1437 NWHoZ25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzOXXZKSzVyPUe0MlQxPDhizszN M{KwN3NCVkeHUh?=
U-266 NH3YdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDGTWM2OD15NT60OVE3KM7:TR?= NFi2PINUSU6JRWK=
MC116 NXPwbW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX4Zm11UUN3ME23OU42PzB6IN88US=> MU\TRW5ITVJ?
PANC-10-05 NETwV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr3TWM2OD15Nz60NlQ{KM7:TR?= NIfmXnFUSU6JRWK=
KYSE-180 NFO4WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTd5LkW0OVQh|ryP MWPTRW5ITVJ?
JAR MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSzTphyUUN3ME23PU4xPTR4IN88US=> MVjTRW5ITVJ?
CAL-62 NGjDb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P3VGlEPTB;OECuNFk2KM7:TR?= MWrTRW5ITVJ?
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJe5dKSzVyPUiwMlIyPTRizszN M3TYRnNCVkeHUh?=
PANC-08-13 Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRThzLkG3Olgh|ryP MWHTRW5ITVJ?
HSC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X0UmlEPTB;OEOuN|A4OSEQvF2= MWrTRW5ITVJ?
HTC-C3 NH3XVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTh|LkS3NFIh|ryP NUmxcm1zW0GQR1XS
KY821 NHnFcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHDTWM2OD16ND6wPFkzKM7:TR?= NFPhPW1USU6JRWK=
DoTc2-4510 NIPtTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTh2LkKxPFUh|ryP NFn4[5lUSU6JRWK=
NCI-H1581 NUfKSFNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTh3LkS2OFEh|ryP M{jDNnNCVkeHUh?=
KARPAS-299 M4LXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;lTWM2OD16Nj6xPVc4KM7:TR?= M3n3WXNCVkeHUh?=
IST-MEL1 NWjxTIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDxTWM2OD16Nj64PFczKM7:TR?= MUHTRW5ITVJ?
KP-N-YS M1HSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnJVnlOUUN3ME24PU46ODJ6IN88US=> MYTTRW5ITVJ?
KYSE-410 NW[5b4FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[2N3VEUUN3ME25NU41ODR{IN88US=> NEHUWplUSU6JRWK=
TE-10 M4fVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\NWG9KSzVyPUmxMlU3OTFizszN M2m4W3NCVkeHUh?=
SK-MEL-1 NG[yUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHXTWM2OD17Mj65NVA3KM7:TR?= Mn7DV2FPT0WU
COLO-792 M1\idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHNng6UUN3ME25OU4zPTZ2IN88US=> M3T1eXNCVkeHUh?=
SCH MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHHcGkyUUN3ME25Ok4{QDd5IN88US=> NXvJRYVuW0GQR1XS
NCI-H1792 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDB[mpPUUN3ME25Ok45QTl{IN88US=> NGHOOGRUSU6JRWK=
NCI-H2029 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL5TWM2OD17Nj65OVY3KM7:TR?= NIjwZ2pUSU6JRWK=
SW684 M{PMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnOdotKSzVyPUm4MlY3PTRizszN M33SXXNCVkeHUh?=
NCI-H209 NELMVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWR3dKSzVyPUGwNE4yOjFizszN M2TIfXNCVkeHUh?=
HLE MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXUU5BKSzVyPUGwOU4zQDJizszN M{PCcHNCVkeHUh?=
GOTO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHJTWM2OD1zMEeuO|c4KM7:TR?= NH3aVJNUSU6JRWK=
NCI-H1793 M4rIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPGTWM2OD1zMEmuNlgh|ryP MUnTRW5ITVJ?
D-392MG M1GzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLlUIxKSzVyPUGxO{4{QThizszN NWjrPFE5W0GQR1XS
SW1990 M1izfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF{MD65OVEh|ryP NWXTWI46W0GQR1XS
ML-2 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LnOWlEPTB;MUKxMlY4PiEQvF2= MWjTRW5ITVJ?
NCI-H2452 NGLUUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfWOpdKSzVyPUGyNk4zOSEQvF2= NVexTY4{W0GQR1XS
SK-MEL-30 NI\Y[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD1zMkOuNlQ1KM7:TR?= MYrTRW5ITVJ?
SN12C NFOydFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF{ND6xO|Yh|ryP M3Ts[nNCVkeHUh?=
NCI-H1770 M{nNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2PWlEPTB;MUK1MlUyPCEQvF2= NUP3VnR[W0GQR1XS
SF268 NUPTfFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD1zMk[uNVU5KM7:TR?= NW\jN2Y6W0GQR1XS
BALL-1 NXvScoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DoUWlEPTB;MUK2MlI{KM7:TR?= NUnK[JA6W0GQR1XS
COLO-679 M{TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnpZnFKSzVyPUGyOk44PTNizszN MVrTRW5ITVJ?
A2780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH1VXBKSzVyPUGyPE46QDhizszN NULUc4FCW0GQR1XS
NCI-H1651 M4rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfHZVNKSzVyPUGzNU4zPDNizszN M1TJNnNCVkeHUh?=
NCI-H2087 NXXMWXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe2VmpKSzVyPUGzNU41QDNizszN M2PTR3NCVkeHUh?=
U-87-MG NYe0cZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF|Mz62NFQh|ryP MlqyV2FPT0WU
LB2518-MEL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LzWGlEPTB;MUO1Mlk6OyEQvF2= MXTTRW5ITVJ?
HCT-116 NFXHeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfwcGhKSzVyPUGzO{4zOTdizszN Mm\OV2FPT0WU
Ca9-22 NYHoXGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXLRWlKSzVyPUGzPU45OzNizszN NHrO[XFUSU6JRWK=
COR-L88 NGPGUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PCSmlEPTB;MUSyMlE1KM7:TR?= MoTlV2FPT0WU
CP50-MEL-B NVi5PFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3XWlEPTB;MUS0MlUxOSEQvF2= M2rVNnNCVkeHUh?=
OVCAR-8 M{njW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfpTWM2OD1zNEWuOlM3KM7:TR?= NWfBXoRRW0GQR1XS
SK-MEL-3 NYXxe|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy3XWpKUUN3ME2xOFcvQDd6IN88US=> Mo\oV2FPT0WU
GT3TKB NVHsWYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljFTWM2OD1zNEmuPVI5KM7:TR?= MXPTRW5ITVJ?
KYSE-450 NFfpRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fVTmlEPTB;MUWxMlU{QSEQvF2= NX7SXIM3W0GQR1XS
CAPAN-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHwTWM2OD1zNUOuNFY1KM7:TR?= MofBV2FPT0WU
BEN MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\0SWlEPTB;MUWzMlkzQCEQvF2= Ml7TV2FPT0WU
NCI-H1304 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXIPGkyUUN3ME2xOVQvPjl2IN88US=> MWPTRW5ITVJ?
KU812 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX0PI1QUUN3ME2xOVgvPjd2IN88US=> NVHGW3Q6W0GQR1XS
Capan-2 NIW1fGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPcZZlUUN3ME2xOlAvPTV|IN88US=> NV3tbZN3W0GQR1XS
A673 M{nPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPMV|B7UUN3ME2xOlEvPzB3IN88US=> MXnTRW5ITVJ?
SAS NWq0d4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTlTWM2OD1zNkKuOlc5KM7:TR?= M2DoNXNCVkeHUh?=
NY NXH2[nRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\0XWlEPTB;MU[1MlMyPCEQvF2= Mn3oV2FPT0WU
HCE-4 NFTrdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH31fmlKSzVyPUG2Ok45PDVizszN MmHGV2FPT0WU
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5Nz61NFMh|ryP M1S3UnNCVkeHUh?=
no-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5OD6xN|Qh|ryP MWDTRW5ITVJ?
MZ7-mel M1fDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraOZRKSzVyPUG3PE41PjdizszN NEPhPIRUSU6JRWK=
NCI-H82 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny5TWM2OD1zOECuNVY2KM7:TR?= NU\lOVU1W0GQR1XS
CAL-72 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF6NT6wOVQh|ryP MYHTRW5ITVJ?
NCI-SNU-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjwXFRKSzVyPUG4Ok45PCEQvF2= NU\OS5lKW0GQR1XS
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD1O2V4UUN3ME2xPFgvOzN|IN88US=> NWjpO45XW0GQR1XS
SCC-9 M3;3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\COGZxUUN3ME2xPVEh|ryP NHjSS5JUSU6JRWK=
KYSE-150 NYDpcHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nJU2lEPTB;MUmxMlg5QCEQvF2= MUfTRW5ITVJ?
HT-29 NGPqbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvmTWM2OD1{MEGuNlEzKM7:TR?= MUTTRW5ITVJ?
COLO-678 NV;VfIt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnYTWM2OD1{MEGuOFUh|ryP MUfTRW5ITVJ?
NCI-H650 NIPFTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzvTFE{UUN3ME2yNFIvOTB|IN88US=> MnzhV2FPT0WU
HuCCT1 NWPrSo13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rVO2lEPTB;MkC0MlIxQCEQvF2= M2PWTnNCVkeHUh?=
SW1116 NUDlRnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD1{MEeuNFc4KM7:TR?= NVLobWttW0GQR1XS
DBTRG-05MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyNz65NFkh|ryP NYTsNYJnW0GQR1XS
SW982 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD1{MEeuPVQ5KM7:TR?= NVewbFFrW0GQR1XS
RCM-1 M1HENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr1d|hKSzVyPUKxOE44PjJizszN MnexV2FPT0WU
COLO-320-HSR NFG3UlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0dVBKSzVyPUKxOk4yOjVizszN M2\JcnNCVkeHUh?=
KNS-42 NGXq[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrvelU1UUN3ME2yNVYvPTd2IN88US=> MnTBV2FPT0WU
C2BBe1 NFrrcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ|MT65NFUh|ryP NUm0Oos4W0GQR1XS
CCRF-CEM NXLNWHNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ2Mz63PVUh|ryP MYLTRW5ITVJ?
SH-4 M2CxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTWTWM2OD1{NE[uNFkh|ryP MmLXV2FPT0WU
LS-1034 NETLUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW4TWM2OD1{NE[uNlY3KM7:TR?= MUPTRW5ITVJ?
NCI-H2347 NVfRdVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qyVGlEPTB;MkS3MlcyOyEQvF2= NIj2S|ZUSU6JRWK=
RPMI-8866 NH7tVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPhTWM2OD1{NEmuNlch|ryP MXrTRW5ITVJ?
GAK NGO1XXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe3R3VTUUN3ME2yOVMvODB{IN88US=> M{LYeHNCVkeHUh?=
NB6 NVX0dWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P1SGlEPTB;MkewMlEh|ryP NGLtcJZUSU6JRWK=
COLO-680N NXfZdJVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTmTWM2OD1{N{KuOVI4KM7:TR?= NGqxWGNUSU6JRWK=
RERF-LC-MS NYHXPJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L6TmlEPTB;Mke2MlAxPyEQvF2= NEHVenlUSU6JRWK=
TGBC11TKB M3ztOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NN45KSzVyPUK3PE4yPzhizszN NHjIbZFUSU6JRWK=
C8166 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXucIdKSzVyPUK3PE42ODZizszN NXjzUHp[W0GQR1XS
HDLM-2 M4DLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j2bWlEPTB;Mkm0MlQxQSEQvF2= NF\KOWVUSU6JRWK=
IGR-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTtVGdKSzVyPUK5OU43PTlizszN MXfTRW5ITVJ?
FADU NF\hdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nQXmlEPTB;Mkm3MlUyKM7:TR?= NEW0UlVUSU6JRWK=
L-428 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\zUGlEPTB;Mkm3MlYyPiEQvF2= NXvFTohDW0GQR1XS
LU-65 NFz3V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrFVGZKSzVyPUOwOE4{OiEQvF2= MYLTRW5ITVJ?
HEL MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[3VYlKSzVyPUOwPU46QDNizszN NWrRXXFHW0GQR1XS
NCI-H810 M3nEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2doJKSzVyPUOxNE42PyEQvF2= NYS4bJhWW0GQR1XS
C3A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNzMT64NFIh|ryP NUDSS|F6W0GQR1XS
NCI-H630 NYqwSY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nJVmlEPTB;M{OyMlI6PCEQvF2= MonrV2FPT0WU
KP-N-YN NIXhcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHjTWM2OD1|NEGuNVI{KM7:TR?= MUTTRW5ITVJ?
MOLT-13 M17xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN2Mj6zNlYh|ryP NVTXT25SW0GQR1XS
NCI-H1993 NFfyeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDLfm5zUUN3ME2zOFIvOzZ3IN88US=> NHG5NlhUSU6JRWK=
BE-13 NGm1RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjsNGdsUUN3ME2zOFQvOTZ5IN88US=> M1P1VHNCVkeHUh?=
IST-SL1 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13IfmlEPTB;M{S3MlQxOSEQvF2= M2f4enNCVkeHUh?=
TE-9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rwXmlEPTB;M{[zMlU5QSEQvF2= MmnLV2FPT0WU
LU-135 NHPR[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN4Nz6wN|Uh|ryP NULNc4llW0GQR1XS
T84 M{PpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJeoZzUUN3ME2zO|QvPzF{IN88US=> MWHTRW5ITVJ?
K-562 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjx[WpKSzVyPUO4N{4{PiEQvF2= MWDTRW5ITVJ?
SBC-5 NWDvbJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN6Nj65PFUh|ryP NEPqbZJUSU6JRWK=
NB17 NYLCcW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrO3BKSzVyPUO5Nk42QTZizszN NV3nfZdRW0GQR1XS
NCI-H2052 NW\lSnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnaTFByUUN3ME2zPVgvPDd{IN88US=> NGXTcpVUSU6JRWK=
HCC38 M{PNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D5OWlEPTB;NECxMlU6OyEQvF2= NHrZTJdUSU6JRWK=
NCI-H69 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LYRWlEPTB;NESxMlA5OyEQvF2= MXzTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[4]
+ 展開

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
細胞試験: [2]
+ 展開
  • 細胞株: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • 濃度: 0, 0.3, 1 and 3 μM
  • 反応時間: 72 or 96 hours
  • 実験の流れ: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • 製剤: Formulated in 30% Captisol
  • 投薬量: 120 mg/kg
  • 投与方法: Orally administered
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
15% Captisol
17 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 480.39
化学式

C25H21N5O.2HCl

CAS No. 1032350-13-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 問題2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt信号経路図

Akt Inhibitors with Unique Features

相関Akt製品

Tags: MK-2206 2HClを買う | MK-2206 2HCl ic50 | MK-2206 2HCl供給者 | MK-2206 2HClを購入する | MK-2206 2HCl費用 | MK-2206 2HCl生産者 | オーダーMK-2206 2HCl | MK-2206 2HCl化学構造 | MK-2206 2HCl分子量 | MK-2206 2HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID